Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

2.

The choreography of HIV-1 proteolytic processing and virion assembly.

Lee SK, Potempa M, Swanstrom R.

J Biol Chem. 2012 Nov 30;287(49):40867-74. doi: 10.1074/jbc.R112.399444. Epub 2012 Oct 5. Review.

3.

Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitor.

Lu M, Felock PJ, Munshi V, Hrin RC, Wang YJ, Yan Y, Munshi S, McGaughey GB, Gomez R, Anthony NJ, Williams TM, Grobler JA, Hazuda DJ, McKenna PM, Miller MD, Lai MT.

Antimicrob Agents Chemother. 2012 Jun;56(6):3324-35. doi: 10.1128/AAC.00102-12. Epub 2012 Mar 5.

4.

Human immunodeficiency virus type 1 capsid mutation N74D alters cyclophilin A dependence and impairs macrophage infection.

Ambrose Z, Lee K, Ndjomou J, Xu H, Oztop I, Matous J, Takemura T, Unutmaz D, Engelman A, Hughes SH, KewalRamani VN.

J Virol. 2012 Apr;86(8):4708-14. doi: 10.1128/JVI.05887-11. Epub 2012 Feb 1.

5.

Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.

Henderson GJ, Lee SK, Irlbeck DM, Harris J, Kline M, Pollom E, Parkin N, Swanstrom R.

Antimicrob Agents Chemother. 2012 Feb;56(2):623-33. doi: 10.1128/AAC.05549-11. Epub 2011 Nov 14.

6.

A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs.

Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF.

Sci Transl Med. 2011 Jul 13;3(91):91ra63. doi: 10.1126/scitranslmed.3002304.

7.

Drug effectiveness explained: the mathematics of antiviral agents for HIV.

Perelson AS, Deeks SG.

Sci Transl Med. 2011 Jul 13;3(91):91ps30. doi: 10.1126/scitranslmed.3002656.

8.

Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor.

Lai MT, Munshi V, Touch S, Tynebor RM, Tucker TJ, McKenna PM, Williams TM, DiStefano DJ, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2009 Jun;53(6):2424-31. doi: 10.1128/AAC.01559-08. Epub 2009 Mar 16.

9.

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs.

Shen L, Peterson S, Sedaghat AR, McMahon MA, Callender M, Zhang H, Zhou Y, Pitt E, Anderson KS, Acosta EP, Siliciano RF.

Nat Med. 2008 Jul;14(7):762-6. doi: 10.1038/nm1777. Epub 2008 Jun 15.

Items per page

Supplemental Content

Write to the Help Desk